Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions.

Oncol Ther · 2022 · PMC9098731 · PMID 35103936

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

fairly significantno p-value reported

Currently, the choice of indications for allo-SCT in patients with high-risk MM or R/R MM is fairly significant [ 26 – 28 , 32 , 34 , 79 ].

also in 581 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.